Investor & Media

Company Overview

Rubius Therapeutics is a biopharmaceutical company pioneering the development of a new class of medicines. Our proprietary RED PLATFORMTM was designed to genetically engineer and culture Red Cell TherapeuticsTM that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas.

Our initial focus is to advance Red Cell Therapeutics product candidates for the treatment of rare diseases, cancer and autoimmune diseases based on three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction.

We plan to file our first Investigational New Drug application (IND) for RTX-134 for the treatment of phenylketonuria during the first quarter of 2019. We are planning to file additional INDs in 2019, 2020 and thereafter.

Press Releases

September 14, 2018
Rubius Therapeutics Added to Russell 2000 and 3000 Indexes

CAMBRIDGE, Mass. , Sept. 14, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, today announced that the company will be added to the quarterly update of the Russell 2000 ® and 3000

Additional Formats
View All

Corporate Presentation

Corporate Fact Sheet